Signadori Bio Raises €11M to Advance Tumour Platform

Why It Matters

Monocyte‑based, off‑the‑shelf immunotherapies could broaden access to effective solid‑tumour treatments, reshaping the oncology market.

Key Takeaways

• Signadori secured €11M ($11.9M) seed extension for monocyte platform.
• Focus on in vivo monocyte engineering targets solid tumour microenvironment.
• Taiho Ventures leads round, adding oncology expertise and strategic support.
• New CEO Selwyn Ho steers company toward clinical development milestones.

Pulse Analysis

The oncology field has been dominated by CAR‑T therapies, which have transformed blood cancer treatment but struggle against solid tumours due to an immunosuppressive microenvironment. Signadori Bio’s approach pivots to the innate immune system, reprogramming circulating monocytes in vivo to become anti‑tumour agents. By leveraging the p21 protein as a master regulator of myeloid activity, the platform promises a scalable, off‑the‑shelf solution that could sidestep the logistical hurdles of autologous cell manufacturing.

The €11 million seed extension, equivalent to roughly $11.9 million, was anchored by Taiho Ventures and backed by returning investors Sofinnova Partners and Invivo Partners. The capital will fund three core objectives: advancing the flagship candidate SiB‑2101 toward lead status, refining delivery mechanisms that edit monocytes directly in the bloodstream, and expanding the scientific team at the HIVE Innovation Center in Paris‑Saclay. Taiho’s involvement brings deep oncology expertise and potential pathways to later‑stage partnerships, positioning Signadori for accelerated preclinical milestones within an 18‑month horizon.

If successful, Signadori’s monocyte platform could disrupt the current immunotherapy landscape, offering a more universal treatment that bypasses patient‑specific cell extraction and expansion. Investors are watching closely as the market seeks alternatives to CAR‑T’s high cost and limited solid‑tumour efficacy. The company’s recent leadership change, with veteran immuno‑oncology executive Dr. Selwyn Ho at the helm, adds credibility to its development roadmap and may attract further strategic funding as the platform moves toward early‑phase clinical trials.